Vivani Medical (NASDAQ:VANI) Director Acquires $1,999,999.26 in Stock

Vivani Medical, Inc. (NASDAQ:VANI) Director Gregg Williams acquired 1,587,301 shares of the stock in a transaction dated Friday, May 15th. The stock was acquired at an average cost of $1.26 per share, with a total value of $1,999,999.26. Following the completion of the transaction, the director owned 34,531,785 shares in the company, valued at approximately $43,510,049.10. This represents a 4.82% increase in their position. The acquisition was disclosed in a filing with the SEC, which is accessible through this link.

Gregg Williams also recently made the following trade(s):

• On Wednesday, April 15th, Gregg Williams acquired 1,587,301 shares of Vivani Medical stock. The stock was acquired at an average cost of $1.26 per share, for a total transaction of $1,999,999.26.
• On Sunday, March 15th, Gregg Williams bought 1,575,231 shares of Vivani Medical stock. The shares were acquired at an average price of $1.07 per share, for a total transaction of $1,685,497.17.

Vivani Medical Price Performance

NASDAQ VANI opened at $1.14 on Tuesday. The business has a 50 day simple moving average of $1.18 and a 200 day simple moving average of $1.29. Vivani Medical, Inc. has a one year low of $0.92 and a one year high of $1.92. The stock has a market capitalization of $98.31 million, a P/E ratio of -2.85 and a beta of 2.35.

Vivani Medical (NASDAQ:VANI) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.08) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.08). Equities analysts expect that Vivani Medical, Inc. will post -0.3 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright dropped their target price on shares of Vivani Medical from $4.00 to $3.50 and set a “buy” rating on the stock in a research report on Tuesday, March 31st. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Vivani Medical presently has an average rating of “Hold” and a consensus target price of $3.50.

Institutional Trading of Vivani Medical

Large investors have recently made changes to their positions in the company. Tudor Investment Corp ET AL bought a new stake in Vivani Medical in the 4th quarter valued at about $1,127,000. Marshall Wace LLP bought a new position in Vivani Medical in the fourth quarter worth approximately $174,000. State Street Corp grew its stake in Vivani Medical by 12.5% in the fourth quarter. State Street Corp now owns 144,865 shares of the company’s stock valued at $178,000 after acquiring an additional 16,070 shares during the period. Jane Street Group LLC acquired a new stake in Vivani Medical in the fourth quarter valued at approximately $60,000. Finally, Renaissance Technologies LLC increased its holdings in shares of Vivani Medical by 118.4% during the fourth quarter. Renaissance Technologies LLC now owns 97,985 shares of the company’s stock valued at $121,000 after acquiring an additional 53,127 shares in the last quarter. 6.78% of the stock is currently owned by institutional investors and hedge funds.

About Vivani Medical

Vivani Medical Solutions, Inc (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.

The company’s flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity.